Daily Cardiology Research Analysis
Analyzed 199 papers and selected 3 impactful papers.
Summary
Today’s top cardiology research spans practice-changing randomized evidence for early surgery in asymptomatic very severe aortic stenosis, a pivotal phase 3 trial of an oral PCSK9 inhibitor achieving large LDL-C reductions, and a multinational diagnostic study establishing optimized cutoffs for the new hs-cTnT gen6 assay. Together, these studies may shift timing of valve intervention, expand lipid-lowering options beyond injections, and refine emergency MI rule-in/rule-out pathways.
Research Themes
- Early intervention strategies in valvular heart disease
- Next-generation lipid-lowering therapies (oral PCSK9 inhibition)
- Optimization of high-sensitivity troponin algorithms for MI diagnosis
Selected Articles
1. Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years.
In asymptomatic very severe aortic stenosis, early surgical aortic valve replacement substantially reduced 10-year operative/cardiovascular mortality and all-cause mortality compared with conservative care. The hazard ratio for the primary endpoint was 0.10, with an absolute 18% reduction in 10-year operative/cardiovascular death.
Impact: This long-term randomized evidence addresses a key timing question and supports earlier intervention, likely influencing guideline recommendations.
Clinical Implications: For asymptomatic patients with very severe aortic stenosis, clinicians should consider early SAVR rather than watchful waiting to lower long-term operative/cardiovascular mortality.
Key Findings
- Early surgery vs conservative care: primary endpoint 3% vs 24% (HR 0.10, 95% CI 0.02–0.43, P=0.002).
- 10-year operative/cardiovascular death: 1% (early) vs 19% (conservative).
- All-cause mortality: 15% (early) vs 32% (conservative), HR 0.42 (95% CI 0.21–0.86).
Methodological Strengths
- Randomized, intention-to-treat analysis with 10-year follow-up.
- Clinically hard endpoints with clear effect sizes.
Limitations
- Single-country trial with modest sample size (N=145) may limit generalizability.
- Applies to very severe AS; not all asymptomatic severe AS phenotypes.
Future Directions: Head-to-head comparisons of early SAVR vs early TAVR in asymptomatic very severe AS, and biomarker/imaging-triggered strategies to refine timing.
BACKGROUND: Among asymptomatic patients with severe aortic stenosis, a previous analysis showed that the risk of a composite of death during surgery or within 30 days after surgery (called operative mortality) or death from cardiovascular causes was significantly lower with early surgery than with conservative care. However, the long-term survival benefit of early surgery, as compared with conservative care, remains unclear. METHODS: We randomly assigned asymptomatic patients with very severe aortic stenosis (defined as an aortic-valve area of ≤0.75 cm RESULTS: A total of 145 patients underwent randomization. In an intention-to-treat analysis, a primary end-point event occurred in 2 of 73 patients (3%) in the early-surgery group and in 17 of 72 (24%) in the conservative-care group (hazard ratio, 0.10; 95% confidence interval [CI], 0.02 to 0.43; P = 0.002). At 10 years, the cumulative incidence of operative mortality or death from cardiovascular causes was 1% in the early-surgery group and 19% in the conservative-care group. Death from any cause occurred in 11 patients (15%) in the early-surgery group and in 23 (32%) in the conservative-care group (hazard ratio, 0.42; 95% CI, 0.21 to 0.86). CONCLUSIONS: Among asymptomatic patients with very severe aortic stenosis, early surgery led to a lower risk of a composite of operative mortality or death from cardiovascular causes than conservative care at 10 years. (Funded by the Korean Institute of Medicine; RECOVERY ClinicalTrials.gov number, NCT01161732.).
2. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.
In a 52-week, multinational, double-blind RCT, oral enlicitide reduced LDL-C by 57% at 24 weeks versus placebo, with sustained benefit at 52 weeks and favorable effects on non-HDL-C, apoB, and Lp(a). Safety signals were comparable to placebo, supporting an oral alternative to injectable PCSK9 therapies.
Impact: Oral PCSK9 inhibition with robust LDL-C lowering could transform adherence and access, broadening secondary and high-risk primary prevention options.
Clinical Implications: For high-risk patients not at LDL-C goal or intolerant to injectables, an oral PCSK9 inhibitor may offer potent, convenient lipid lowering alongside statins/ezetimibe; outcomes trials are still needed.
Key Findings
- LDL-C change at week 24: −57.1% with enlicitide vs +3.0% with placebo; adjusted difference −55.8 percentage points (P<0.001).
- Sustained LDL-C lowering at week 52; significant reductions in non-HDL-C, apoB, and Lp(a) at week 24 (all P<0.001).
- Adverse event rates were similar between groups over 52 weeks.
Methodological Strengths
- Multinational, double-blind, randomized, placebo-controlled design.
- Large intention-to-treat population with prespecified secondary endpoints.
Limitations
- Surrogate primary endpoint (LDL-C change) without cardiovascular outcomes.
- Follow-up limited to 52 weeks; long-term safety and adherence beyond 1 year unknown.
Future Directions: Dedicated cardiovascular outcomes trials, long-term safety, and comparative effectiveness versus PCSK9 mAbs/inclisiran and in combination with ezetimibe/statins.
BACKGROUND: Enlicitide decanoate, an oral proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data are needed. METHODS: In this multinational, double-blind, randomized, placebo-controlled trial, we enrolled adults with a history of a major atherosclerotic cardiovascular disease event with an LDL cholesterol level of 55 mg per deciliter or higher and those who were at risk for a first atherosclerotic cardiovascular disease event with an LDL cholesterol level of 70 mg per deciliter or higher. Participants were assigned in a 2:1 ratio to receive enlicitide at a dose of 20 mg or placebo daily for 52 weeks. The primary end point was the mean percent change in LDL cholesterol level from baseline to week 24. Key secondary end points were the mean percent change in LDL cholesterol level at week 52 and the mean percent change in levels of non-high-density lipoprotein (non-HDL) cholesterol and apolipoprotein B and the percent change in lipoprotein(a) level at week 24. RESULTS: Of the 2909 participants in the intention-to-treat population, 1935 received enlicitide and 969 received placebo (5 did not receive enlicitide or placebo). The mean age of the participants was 63 years, and 39.3% were women. The mean (±SD) LDL cholesterol level at baseline was 96.1±38.9 mg per deciliter. The mean percent change in LDL cholesterol levels at week 24 was -57.1% (95% confidence interval [CI], -61.8 to -52.5) with enlicitide and 3.0% (95% CI, 0.9 to 5.1) with placebo, representing an adjusted between-group difference of -55.8 percentage points (95% CI, -60.9 to -50.7; P<0.001). The mean percent change in LDL cholesterol level at week 52, the mean percent changes in non-HDL cholesterol and apolipoprotein B levels at week 24, and the percent change in lipoprotein(a) levels at week 24 were significantly greater with enlicitide than with placebo (P<0.001 for all comparisons). The incidence of adverse events did not appear to differ between the groups. CONCLUSIONS: Among participants who had a history of or were at risk for a first atherosclerotic cardiovascular disease event, treatment with the oral PCSK9 inhibitor enlicitide resulted in significantly lower LDL cholesterol levels than placebo at 24 weeks. (Funded by MSD [Rahway, NJ]; CORALreef Lipids ClinicalTrials.gov number, NCT05952856.).
3. High-Sensitivity Cardiac Troponin T-gen6 Assay in Suspected Myocardial Infarction: Diagnostic Accuracy, Cutoffs, and Clinical Implications.
In 3,346 patients with suspected MI, hs-cTnT gen6 achieved 100% sensitivity for early rule-out at <6 ng/L and high-specificity rule-in at ≥112 ng/L or with appropriate deltas. Algorithm-specific gen6 thresholds enable safe discharge of up to ~56% (0/1-hour) while maintaining near-perfect sensitivity.
Impact: Assay-specific cutoffs for a next-generation hs-cTnT support safer, faster MI triage and resource optimization in emergency care.
Clinical Implications: Adopting gen6-specific 0/1- and 0/2-hour thresholds may increase early discharge without compromising safety, but requires local validation and protocol updates.
Key Findings
- Rule-out: gen6 <6 ng/L yielded 100% sensitivity irrespective of chest pain onset; extended 0/1-h strategy ruled out 56.3% with 99.7% sensitivity.
- Rule-in: gen6 ≥112 ng/L or 0/1-h delta ≥10 ng/L ruled-in 20.0% with 93.4% specificity; 0/2-h delta ≥15 ng/L ruled-in 23.9% with 92.7% specificity.
- Gen6 identified fewer patients as ‘injury’ (35.9%) than gen5 (43.5%), potentially reducing false positives.
Methodological Strengths
- International prospective diagnostic cohort with central adjudication.
- Internal and external validation of assay-specific cutoffs.
Limitations
- Secondary analysis; clinical impact on outcomes and overcrowding not directly tested.
- Implementation requires local assay calibration and pathway adjustments.
Future Directions: Prospective implementation trials assessing safety, admissions, length of stay, costs, and patient-centered outcomes using gen6 algorithms.
BACKGROUND: The new high-sensitivity cardiac troponin (hs-cTn) T-generation (gen) 6 assay has higher analytical sensitivity than the current hs-cTnT-gen5 assay, but its clinical performance is unknown. OBJECTIVES: The authors aimed to assess the clinical performance and use-optimized cutoffs of the hs-cTnT-gen6 assay. METHODS: In this secondary analysis of an international, prospective, diagnostic study with central adjudication, patients presenting with suspected myocardial infarction to the emergency department were enrolled. hs-cTnT-gen6 and hs-cTnT -gen5 were measured at the same time points. The analytical and diagnostic performance of hs-cTnT-gen6 were compared to hs-cTnT-gen5, and assay-specific cutoffs for the European Society of Cardiology 0/1- and 0/2-hour algorithms were derived and internally and externally validated. RESULTS: Among 3,346 patients, myocardial infarction was the final diagnosis in 616 (18.4%). The proportion of patients with concentrations above the upper reference limit and therefore having myocardial injury was lower for hs-cTnT-gen6 (35.9%) than for hs-cTnT-gen5 (43.5%; P < 0.001). Diagnostic accuracy at emergency department presentation, expressed as area under the curve, was 0.927 (95% CI: 0.918-0.937) for hs-cTnT-gen6 and 0.931 (95% CI: 0.921-0.94) for hs-cTnT-gen5. A gen6 cutoff of <6 ng/L ruled out non-ST-segment elevated myocardial infarction in 30.0% of patients with 100% sensitivity (95% CI: 99.4%-100%) irrespective of chest pain onset. An hs-cTnT-gen6 cutoff of <8 ng/L at presentation (if chest pain onset was >3 hours) or <18 ng/L together with a 0/1-hour delta of <2 ng/L ruled out 56.3% with a sensitivity of 99.7% (95% CI: 98.3%-99.9%). An hs-cTnT-gen6 concentration ≥112 ng/L or a 0/1-hour delta ≥10 ng/L ruled-in 20.0% with a specificity of 93.4% (95% CI: 92.0%-94.6%). An hs-cTnT-gen6 cutoff <8 ng/L at presentation (if chest pain onset was >3 hours) or <18 ng/L together with a 0/2-hour delta of <4 ng/L ruled out 51.1% with a sensitivity of 99.7% (95% CI: 98.1%-99.9%). An hs-cTnT-gen6 concentration ≥112 ng/L or a 0/2-hour delta ≥15 ng/L ruled-in 23.9% with a specificity 92.7% (95% CI: 90.8%-94.2%). Findings were consistent in sensitivity analyses as well as in the external validation cohort. CONCLUSIONS: The novel hs-cTnT-gen6 assay demonstrated excellent and comparable diagnostic performance to the established hs-cTnT-gen5 assay with fewer patients identified as having myocardial injury. Use-optimized, assay-specific cutoffs for the European Society of Cardiology 0/1- and 0/2-hour algorithms provided very high sensitivity and high specificity. (Advantageous Predictors of Acute Coronary Syndromes Evaluation Study [APACE]; NCT00470587).